GlassScriptPhysician profile
Panayotis Ledakis
NPI 1649385634
$15,176.86
in general payments reported to CMS, 2019-2025
43 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,950 · 2020: $1,277 · 2021: $22.79 · 2022: $215 · 2023: $8,106 · 2024: $1,182 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,800 · Food and Beverage: $3,187 · Travel and Lodging: $586 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,800.00 |
| Food and Beverage | $3,187.34 |
| Travel and Lodging | $586.38 |
| Education | $139.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $7,580.29 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $3,092.29 | 2019-2020 | |
| Abbvie INC. | $459.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.99 | 2019-2025 | Opdivo |
| Intera Oncology, INC | $322.04 | 2024 | Intera |
| Pfizer INC. | $315.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $288.74 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $248.73 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Novartis Pharmaceuticals Corporation | $246.02 | 2019-2025 | |
| Eisai INC. | $178.97 | 2020-2025 | |
| Glaxosmithkline, LLC. | $163.41 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Seagen INC. | $158.01 | 2019-2025 | Tivdak |
| Pharmacyclics LLC, An Abbvie Company | $139.29 | 2019-2023 | Imbruvica, Epkinly |
| Caris Mpi, INC. | $129.06 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $112.08 | 2023-2025 | Libtayo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Panayotis Ledakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.